The relationship between trastuzumab and Euched

The relationship between Fam-trastuzumab deruxtecan-nxki and Enhertu is actually different names for the same drug. Trastuzumab is its scientific name, and Uhide is the trade name of Trastuzumab marketed in China.

This drug was jointly developed by the British company AstraZeneca and Japan's Daiichi Sankyo. It is an antibody-drug conjugate (ADC), which is conjugated from a humanized monoclonal antibody to a linker containing a cytotoxic drug. It specifically targets HER2-positive tumor cells. Through a unique mechanism, Trastuzumab (Uhide) can accurately deliver chemotherapy drugs to the tumor site, thereby achieving high efficiency and low side effects. In clinical trials, trastuzumab demonstrated excellent therapeutic effects, significantly extending the survival of patients with HER2-positive breast cancer and reducing the risk of disease progression. At the same time, its safety has also been fully verified, allowing patients to better protect their quality of life during treatment.

The launch of trastuzumab is undoubtedly great news for breast cancer patients. It not only provides patients with new treatment options, but also marks the continuous progress and development in the field of breast cancer treatment. The domestically marketed generic version of Trastuzumab is a strictly controlled drug and has not yet entered the scope of medical insurance. The price per box of 100 mg is about RMB 10,000 or more; the price per box of the Hong Kong version and the Hong Kong original version is around RMB 15,000 (the price may fluctuate due to the exchange rate). The ingredients of the two drugs are basically the same, and there are currently no generic versions of Trastuzumab on the market.